Linehan

Stefan Linehan Promoted to Vice President of Operations and Development at TissueVision, Inc.

Retrieved on: 
Wednesday, March 30, 2022
Health, General Health, Research, Radiology, Science, Biotechnology, Photon, WIL Research Laboratories, Wyeth, Leadership, Maternity leave and the Organisation for Economic Co-operation and Development, 3D, Growth, Good laboratory practice, Neuroscience, Research, Environment, Cancer, Dermatology, CEO, Tissue, Documentation, Autoradiograph, Solution, Linehan, MSI, Medical imaging

TissueVision, Inc., a leading provider of life sciences imaging solutions, announced today the promotion of Stefan Linehan to Vice President of Operations and Development.

Key Points: 
  • TissueVision, Inc., a leading provider of life sciences imaging solutions, announced today the promotion of Stefan Linehan to Vice President of Operations and Development.
  • In his new role, Linehan will expand TissueVisions service offerings through strategic partnerships with clients and industry organizations.
  • He will continue to oversee sales and growth of TissueVisions Serial Two-Photon Plus (STP2) imaging and solutions platform.
  • Previously, Linehan oversaw mass spectrometry imaging (MSI) services as Director of North America and Head of Japan at ImaBiotech.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Coinbase Global, Inc. (COIN)

Retrieved on: 
Friday, July 30, 2021
Legal, Professional services, Transport, Land transport, Coinbase, Linehan, Traffic congestion, Toll road, Class action

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On this news, Coinbases stock fell $9.24, or 3.7%, to close at $239.00 per share on May 18, 2021, thereby injuring investors.
  • Then, on May 19, 2021, Coinbase announced technical problems, including delaysdue to network congestion affecting those who wanted to withdraw their money.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Frequency Therapeutics, Inc. (FREQ)

Retrieved on: 
Friday, July 16, 2021
Limited liability partnership, Partnerships, Glancy, Class action, Linehan, Surname, Names

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • Frequency Therapeutics has conducted several clinical studies evaluating the safety and effectiveness of FX-322, the most significant which was a Phase 2a study that began in October 2019.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Frequency Therapeutics, Inc. (FREQ)

Retrieved on: 
Friday, July 9, 2021
Limited liability partnership, Partnerships, Glancy, Class action, Linehan, Surname, Names

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • Frequency Therapeutics has conducted several clinical studies evaluating the safety and effectiveness of FX-322, the most significant which was a Phase 2a study that began in October 2019.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Rekor Systems, Inc. f/k/a Novume Solutions, Inc. (REKR)

Retrieved on: 
Thursday, July 8, 2021
Legal, Professional services, Linehan, Rekor, Advertising, Toll-free telephone number

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • The same day, during a conference call, Rekor indicated that the Company may not secure a UVED agreement with Texas.
  • On this news, the Companys stock price fell $5.20, or 27.5%, to close at $13.71 per share on May 10, 2021, thereby injuring investors.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Frequency Therapeutics, Inc. (FREQ)

Retrieved on: 
Thursday, June 17, 2021
Legal, Professional services, Linehan, Class action

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • Frequency Therapeutics has conducted several clinical studies evaluating the safety and effectiveness of FX-322, the most significant which was a Phase 2a study that began in October 2019.
  • On this news, Frequencys shares fell $28.30, or 78%, to close at $7.99 per share, thereby damaging investors.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against SOS Limited (SOS)

Retrieved on: 
Tuesday, May 25, 2021
Civil law, Class action, Limited liability partnership, Glancy, Linehan, Surname, Names, Civil law, Class action, Limited liability partnership, Glancy, Linehan, Surname, Names

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • They also claimed that FXK Technology Corporation (FXK), which SOS announced it would purchase, was actually an undisclosed related party shell.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against ChemoCentryx, Inc. (CCXI)

Retrieved on: 
Thursday, May 13, 2021
Legal, Professional services, Shareholder, Stock market, Linehan, eMail

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.\nChemoCentryx is a biopharmaceutical company.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.\nChemoCentryx is a biopharmaceutical company.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected] , or visit our website at www.glancylaw.com .
  • If you inquire by email please include your mailing address, telephone number and number of shares purchased.\nThis press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210513005117/en/\n"

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Volkswagen AG (VWAGY)

Retrieved on: 
Wednesday, May 12, 2021
Legal, Professional services, Shareholder, Stock market, Linehan, Toll-free telephone number

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.\nOn March 29, 2021, Volkswagen published a draft press release announcing its American subsidiaries\xe2\x80\x99 supposed name change to \xe2\x80\x9cVoltswagen.\xe2\x80\x9d Media outlets reported that they confirmed with the Company that the name change was real.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.\nOn March 29, 2021, Volkswagen published a draft press release announcing its American subsidiaries\xe2\x80\x99 supposed name change to \xe2\x80\x9cVoltswagen.\xe2\x80\x9d Media outlets reported that they confirmed with the Company that the name change was real.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected] , or visit our website at www.glancylaw.com .
  • If you inquire by email please include your mailing address, telephone number and number of shares purchased.\nThis press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210512005243/en/\n'

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Arcimoto, Inc. (FUV)

Retrieved on: 
Monday, May 10, 2021
XC2, Toll-free telephone number, Shareholder, Linehan

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.\nOn March 23, 2021, Bonitas Research published a report alleging that Arcimoto had delivered \xe2\x80\x9cless than 5%\xe2\x80\x9d of the pre-orders it had touted since 2018 and that the Company\xe2\x80\x99s largest customer is secretly owned and operated by an undisclosed related party, FOD Capital, LLC.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.\nOn March 23, 2021, Bonitas Research published a report alleging that Arcimoto had delivered \xe2\x80\x9cless than 5%\xe2\x80\x9d of the pre-orders it had touted since 2018 and that the Company\xe2\x80\x99s largest customer is secretly owned and operated by an undisclosed related party, FOD Capital, LLC.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • If you wish to\xc2\xa0learn more\xc2\xa0about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected] , or visit our website at www.glancylaw.com .
  • If you inquire by email please include your mailing address, telephone number and number of shares purchased.\nThis press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.\nGlancy Prongay & Murray LLP, Los Angeles\n"